Naltrexone effects on short-term and long-term smoking cessation

Journal of Addictive Diseases

Volumn 18, Issue 1, 1999, Pages 31-40

  Covey, Lirio S ^a   Glassman, Alexander H ^a   Stetner, Fay ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; NICOTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISORIENTATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DEPENDENCE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PANIC; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; STATISTICAL ANALYSIS;

EID: 0032919274     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v18n01_04     Document Type: Article

References (17)

1. Corrigall WA, Coen KM. Opiate antagonsists reduce cocaine but not nicotine self-administration. Psychopharmacol. 1991; 104: 167-170.
2. Opitz K, Weixcher ML. Volitional oral intake of nicotine in tupaias: drug-induced alterations. Drug Alcohol Depend. 1988; 21: 99-104.
3. Gorelick D, Rose J, Jarvik ME. Effect of naloxone on cigarette smoking. J Subst Abuse. 1989; 1: 143-159.
4. Karras A, Kane J. Naloxone reduces cigarette smoking. Life Sci. 1980; 27: 1541-1545.
5. Nemeth-Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacol. 1986; 89: 261-264.
6. Sutherland G, Stapleton JA, Russell MH, C Feyerabend. Naltrexone, smoking behaviour, and cigarette withdrawal. Psychopharmacol. 1995; 120: 418-425.
7. Lerner I, Schneider N, ALA Guide for Clinic Leaders, videotape 4230 (developed for the American Lung Association, 1984; Chicago, MMI Video.
8. Russell MAA. Estimation of smoke dosage and mortality of non-smokers from environmental tobacco smoke. Toxiol Lett. 1987; 35: 9-18.
9. Wald NJ, Boreham J, Bailey A, et al. Urinary cotinine as marker of breathing other people’s tobacco smoke. Lancet. 1984; 1:230-231.
10. Benowitz NL. The use of biologic fluid samples in assessing tobacco smoke consumption, in Grabowski J, Bell CS (eds). Measurement in the Analysis and Treatment of Smoking Behavior, Research Monograph 48. Rockville, MD, National Institute of Drug Abuse, 1983, pp. 6-27.
11. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiat. 1978; 35: 837-844.
12. Hughes JR, Hatsukami DK. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiat. 1986; 43: 289-294.
13. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of nicotine path for smoking cessation: A meta-analysis. JAMA. 1994; 263: 2760-2765.
14. Hurt RD, Sachs DL, Glover ED, Offord KP, Johnston JA, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Eng J Med. 1997; 337: 1195-1202.
15. Glassman AH, Stetner F, Walsh BT, Raizman P, Fleiss JL, Cooper TB, Covey LS. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind randomized trial. JAMA. 1988; 259: 2863-2866.
16. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli S. Fleiss J, Cooper T. Smoking cessation, clonidine, and the vulnerability to nicotine among dependent smokers. Clin Pharmacol and Therapeut. 1993; 54: 670-679.
17. Covey LS, Hughes D, Glassman AG, Blazer D, George LK. Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina Epidemiologic Catchment Area. Tobacco Control. 1994; 3:222-227.